http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#Head
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#assertion
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#provenance
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#pubInfo
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#assertion
http://identifiers.org/drugbank/DB00246
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Drug
http://identifiers.org/drugbank/DB00246
http://www.w3.org/2000/01/rdf-schema#label
Ziprasidone
http://identifiers.org/drugbank/DB00246
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.obolibrary.org/obo/MONDO_0005618
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Disease
http://purl.obolibrary.org/obo/MONDO_0005618
http://www.w3.org/2000/01/rdf-schema#label
Anxiety disorder
http://purl.obolibrary.org/obo/MONDO_0005618
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/MONDO_0005618
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://identifiers.org/drugbank/DB00246
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
http://www.w3.org/2000/01/rdf-schema#label
First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
https://w3id.org/biolink/vocab/aggregator_knowledge_source
https://w3id.org/biolink/infores/knowledge-collaboratory
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
https://w3id.org/biolink/vocab/has_population_context
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#context
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
https://w3id.org/biolink/vocab/publications
http://www.ncbi.nlm.nih.gov/pubmed/31077503
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#association
https://w3id.org/biolink/vocab/relation
http://purl.obolibrary.org/obo/NCIT_C94303
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#context
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Cohort
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#context
http://www.w3.org/2000/01/rdf-schema#label
Adults
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#context
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Cohort
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#provenance
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-7641-6446
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#pubInfo
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#sig
http://purl.org/nanopub/x/hasSignature
CBfkDJ9Nop9ZLjVzcko68A2iQGGE5z8rqxagnCiHI8SFMH0PIs52suDMXedxMr1zwS82mtzq6tEoCq1dxRxSTc9f1DL5CchipEHKztv3vhILtQfRho5NwHLZO7cBHFj7GyBMJB39XVfB74w9o12/NeMmx4Dtw20HxPDoiXOVIxo=
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.w3.org/ns/prov#generatedAtTime
2022-09-16T11:51:15.134717
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1501-1082
http://purl.org/np/RA5fghTqOqBxtvOs-k77DSpG8LmFWg4EPX2sEiOvJjEbI
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY
https://w3id.org/biolink/vocab/
http://purl.org/pav/version
2.3.0